



Short form announcement


This announcement is a condensed version of the full announcement in respect of the reviewed provisional financial results announcement for the year ended 30 June 2014 of the Group and as such it does not contain full or complete details pertaining to the Group's results. Any investment decisions should be made based on the full announcement. The full announcement has been published on the JSE News Service (SENS) and can be found on the Group's website (www.aspenpharma.com). It is also available for inspection at our registered office, Building 8, Healthcare Park, Woodlands Drive, Woodmead or from the Company Secretary (rverster@aspenpharma.com) and the offices of our sponsor, Investec Bank Limited, 100 Grayston Drive, Sandown, from 9:00 to 16:00 weekdays at no charge. This summarised announcement is the responsibility of the Board of Directors of Aspen and has been approved by the Board of Directors on 10 September 2014.




Revenue (R' billion)



Operating profit (R' billion)



Normalised headline earnings per share (cents)



Condensed statement of financial position



	Change	Year ended June 2014 R'million	Year ended June 2013 R'million
Non-current assets		51 334,6	29 644,7
Current assets		31 212,8	15 777,0
Total assets		82 547,4	45 421,7
Capital and reserves		28 876,1	22 798,9
Non-current liabilities		37 629,3	9 757,5
Current liabilities		16 042,0	12 865,3
Total equity and liabilities		82 547,4	45 421,7
Net asset value	27%	28 876,1	22 798,9
Net asset value per share (cents)	26%	6 333,3	5 007,3

Condensed statement of cash flows

	Year ended June 2014 R'million	Year ended June 2013 R'million
Cash generated from operating activities	3 836,3	3 986,1
Cash used in investing activities	(20 850,4)	(6 283,2)
Cash generated from financing activities	19 447,5	3 610,7
Effects of exchange rate changes	312,2	112,8
Movement in cash and cash equivalents	2 745,6	1 426,4
Cash and cash equivalents at beginning of the year	3 416,2	1 989,8
Cash and cash equivalents at end of the year	6 161,8	3 416,2
Diluted operating cash flow per share (cents)	840,9	874,1

Condensed statement of comprehensive income

	Change	Year ended June 2014 R'million	Year ended June 2013 R'million
Revenue	53%	29 515,1	19 308,0
Cost of sales		(15 793,2)	(10 077,3)
Gross profit		13 721,9	9 230,7
Net expenses	50%	(6 297,1)	(4 187,3)
Operating profit	47%	7 424,8	5 043,3
Net finance costs		(1 068,3)	(553,9)
Tax		(1 351,0)	(975,3)
Profit for the year	42%	5 005,5	3 514,1



DIRECTORS: N J Dlamini (Chairman)*, R C Andersen*, M G Attridge, M R Bagus*, J F Buchanan*, K D Dlamini*, S A Hussain*, M M Manyama-Matome*
C N Mortimer*, S B Saad, S V Zilwa* *Non-executive director
COMPANY SECRETARY: R Verster
Maureen Manyama-Matome was appointed as a non-executive director on 1 June 2014.
REGISTERED OFFICE: Building Number 8, Healthcare Park, Woodlands Drive, Woodmead
SPONSOR: Investec Bank Limited
TRANSFER SECRETARY: Computershare Investor Services Proprietary Limited / (Registration number 2004/003647/07)
70 Marshall Street, Johannesburg, 2001 (PO Box 61051, Marshalltown, 2107).